Drug Approval | July 26, 2023
Lupin receives approval from TGA Australia for Tiotropium Dry Powder
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
This product will be manufactured at Lupin's Pithampur facility in India
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Pfizer is likely to show GSK significant competition
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Subscribe To Our Newsletter & Stay Updated
